AI-assisted molecular design of quinolone alkaloid analogues as pancreatic lipase inhibitor candidates
Pancreatic lipase (PL) is a key enzyme in dietary fat absorption and a validated target for preventing obesity. However, the existing PL inhibitors, such as orlistat, have side effects. We developed a molecular design workflow that integrates machine-learning-based generation with iterative docking simulations, focusing on quinolone-alkaloid-like scaffolds. The docking score of the best candidate decreased from -8.0 to -13.5 kcal/mol over 60 optimization cycles. The top-scoring structure contained a polycyclic aromatic core linked via conjugated chains, with docking poses indicating π–π stacking with Tyr114 and Phe215, consistent with a pocket-blocking mechanism that impeded substrate entry. Additionally, we observed a polar approach near Ser152. The generator produced chemotypes that resembled known inhibitors despite starting from quinolone alkaloid scaffolds. Although we focused on docking-based optimization, these findings demonstrate the potential of AI-assisted molecular design for identifying novel PL inhibitors. Further validation is required, including systematic structure-activity analyses and experimental testing.
Authors
- Hayato Suzuki (ORCID: https://orcid.org/0000-0001-6120-9471)
- Yukiko Matsuo (ORCID: https://orcid.org/0000-0003-0928-2879)
- Yoh Noguchi
- Ryota Morikawa (ORCID: https://orcid.org/0000-0001-9958-9756)
- Motokuni Nakajima (ORCID: https://orcid.org/0009-0006-3834-4388)
- Chiawen Ying
- Kaito Watanabe
- Masako Takasu
Publication Details
- Journal
- Springer Link (Chiba Institute of Technology)
- Published
- 2026-04-24
- DOI
- https://doi.org/10.1051/bioconf/202623202001/pdf
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00